Health officials in the US have been told to prepare for a COVID-19 vaccine to be ready by November ahead of the US presidential elections, according to press reports.
GlaxoSmithKline and US-based Vir Biotechnology are to trial a new therapy for COVID-19 based on an antibody designed to neutralise the SARS-CoV-2 coronavirus.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
